Hematopathology Fellowship Program

The Hematopathology Fellowship Program at City of Hope is a two-year program primarily designed for fellows interested in academic hematopathology. Supporting one of the largest bone marrow transplantation programs in the United States, and enjoying an active consultation service, the program evaluates more than 3,000 diagnostic specimens involving peripheral blood, bone marrow, lymph nodes and extranodal biopsies each year. The program has a rich history, which includes notable past faculty such as Drs. Henry Rappaport, Daniel Arber and Lawrence Weiss. Multiparameter studies are emphasized, including analyses by morphology, immunohistochemistry, flow cytometry, and cytogenetic and molecular techniques, all supported by active in-house laboratories. 
 
The first fellowship year is Accreditation Council for Graduate Medical Education (ACGME)  accredited and focuses on diagnostic hematopathology. Didactic lectures, Pathology Grand Rounds, slide seminars, patient care conferences, bimonthly research meetings and a journal club are part of the educational experience. During the second year, fellows continue their research projects and participate as instructors in independent hematopathology case sign out within the division, preparing them for academic careers.
 
Contact Information
 
Ofelia Kiedpool,
Hematopathology Coordinator - Department of Pathology
City of Hope
1500 E. Duarte Road
Duarte, CA  91010
626-218-3497
 
Program Faculty
 
 
 
 
 
 
 
 
 
 
 
Requirements
 
Candidates must be in good standing in an ACGME accredited program in Anatomic and Clinical Pathology, (or equivalent program in Canada recognized by American Board of Pathology), and be eligible for Pathology Boards and a California medical license upon completion of residency training.
 
Positions and Application Process
 
Up to three ACGME accredited positions are available each year. For positions beginning in July, please send a brief cover letter, three reference letters and CV (or standardized fellowship application from CAP) at least a year and a half in advance (e.g., September 2019 for a July 2021 start date) to:
 
Attn: Ofelia Kiedpool,
Hematopathology Coordinator - Department of Pathology
City of Hope
1500 E. Duarte Road
Duarte, CA  91010
626-218-3497
 
Select Presentations and Publications Written by Faculty and Fellows
 
 
  • Cantu D, Pillai R, Homan S, Nathwani B, Weisenburger D. “Blastic transformation of mantle cell lymphoma with B-lymphoblastic features”. Human Pathology:  Case Reports. 2019
  • Cloe AL, Padeganeh A, Bedell V, Song J et al. Single Nuclear Polymorphism Study with Oncoscan Demonstrates Recurrent Abnormalities Involving Chromosomes 9, 13, and 17 in Blastic Plasmacytoid Dendritic Cell Neoplasm. USCAP 2019
  • Cheng JX, Chen L, Li Y, Cloe AL, et al. RNA Cytosine Methulation and Methyltransferases Mediate Chromatin Organization and 5-azacytidine Response and Resistance in Leukemia.  Nature Communications. 2018; 9. 
  • Song JY, Cloe A, Ali S, Siaghani PJ, Himchak E, Cantu D, Wanda Chan, Quirk E, Weisenburger D, Aoun P. “Bone marrow adequacy: Comparison of assisted versus unassisted bedside collections by a laboratory technologist.” USCAP 2019
  • Ali S. “The Kids are Marginalized and Still Alright. A case of pediatric marginal zone lymphoma.” Los Angeles Society of Pathology Case Presentation, April 2019
  • Ali S, Song JY, Kim Y, Gaal K, “An acute presentation of systemic mastocytosis with associated hematologic neoplasm after a long-standing history of transfusion dependent anemia.” Workshop of the Society for Hematopathology/European Association for Hematopathology, 2019
  • Ali S, Aoun P, Telatar M, Weisenburger D, Nakamura R, Stein A, Song JY, Gaal K, Kim Y, Aldoss I, Salhotra A, Yew H, Pillai R, Afkhami M. “BCOR Mutations in the Myeloid Malignancies: A One-Year Experience at a Comprehensive Cancer Center”. USCAP, Vancouver, Canada. March 2018.
  • Cantu D, Cloe A, Song JY, Weisenburger DDW, Chen YY, Williams B, Kim Y. “Diagnostic Application of CyTOF in Hodgkin Lymphoma.” USCAP, Vancouver, Canada. March 2018.
  • Cantu D, Cloe A, Song JY, Weisenburger DDW, Chen YY, Williams B, Kim Y. “Measuring Tumor Microenvironment in Classical Hodgkin Lymphoma using CyTOF.” USCAP, Vancouver, Canada. March 2018.
  • Cloe A., et al. “Novel Fusion of TCF3-MEF2B in BCR-ABL Negative B-Lymphoblastic Leukemia.” USCAP, Vancouver, Canada. March 2018.
  • Himchak E, Muirhead D, Lewallen M, Song JY, Kim Y, Nathwani B, Weisenburger D, Herrera A, Pillai R. “Evaluation of the Tumor Microenvironment Using Multiplex Immunohistochemistry.” USCAP, Vancouver, Canada. March 2018.
  • Siaghani P, Yang L, Zhao L, Telatar M, Cuellar M, Himchak E, Yin H, Weisenburger D, Aoun P, Afkhami M, Pillai M. “High sensitivity detection of IDH1/2 mutations for assessment of minimal residual disease.” USCAP, Vancouver, Canada. March 2018.
  • Wong JT, Fidai S, Song JY, et al. Subcutaneous panniculitis-like T-cell lymphoma. In: Shao H, ed. Cutaneous T-cell Lymphoma (CTCL): Clinical Features, Diagnosis and Treatment Options. Hauppauge NY: Nova Science Publishers. 2017.
  • Wong J, Ameri MD, Siaghani P, Cantu D, Chen Y-Y, Song J, Weisenburger DD, Kim Y. Programmed Cell Death Ligand 1 (PD-L1) Expression in the Follicular Lymphoma Microenvironment. United States and Canadian Academy of Pathology 2017.
  • Song JY, Kim YS, Siaghani P, Cantu D, Chen YY, Pillai R, Chan WC, Weisenburger DD. CTLA-4 expression in Hodgkin lymphoma confers a worse overall survival in relapsed/refractory patients (Platform presentation at the USCAP 2017 meeting).
  • Wong J, Ameri MD, Siaghani P, Cantu D, Chen Y-Y, Song J, Weisenburger DD, Kim Y. Defining True Cellularity in Age-Matched Marrows. United States and Canadian Academy of Pathology 2017.
  • Al Malki MM, Song JY, Yang D, Cao T, Aldoss I, Mokhtari S, Dadwal S, Gendzekhadze K, Pawlowska A, Ameri M, Marcucci G, Karanes C, Parker P, Snyder D, Senitzer D, Nademanee A, Forman SJ, Nakamura R, Pullarkat V. Transfusion- Related Iron Overload (TRIO) is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT). ASH meeting 2017.
  • Herrera AF, Mei M, Low L, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde E, Chan WC, Chen R, Davids MS, Freedman A, Fisher DC, Jacobsen ED, Jacobson CA, Kim HT, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer J, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Double expressing and double-hit relapsed or refractory diffuse large B-cell lymphoma have inferior survival following autologous stem cell transplantation. Journal of Clinical Oncology. 2017;35(1):24-31. PMID: 28034071.
  • Ameri MD, Wong J, Low L, Chen Y-Y, Weisenburger DD, Pillai R, Kim YS, Song JY, “CXCR4 Expression in Follicular Lymphoma.” USCAP, Seattle, Washington. March 2016.
  • Low L, Song JY, Chen YY, Valle M, Weisenburger DD, Kim YS. Coexpression of MYC and BCL2 Proteins Identifies a Subset of Follicular Lymphoma that Undergoes Transformation to Diffuse Large B-cell Lymphoma and Correlates with Poor Overall Survival (USCAP 2016).
  • Song JY, Song L, Herrera AF, Venkataraman G, Murata-Collins JL, Bedell V, Chen YY, Kim YS, Tadros R, Nathwani BN, Weisenburger DD, Feldman AL. Cyclin D1 expression in Peripheral T-cell lymphomas. Modern Pathology. 2016;29(11):1306-1312. PMID: 27469326.
  • Low LK, Song JY. B-cell Lymphoproliferative Disorders Associated with Primary and Acquired Immunodeficiency. Surgical Pathology Clinics 2016;9:55-77. PMID: 26940268
  • Low L, Song JY, Mei M, Krishnan A, Nademanee A, Popplewell L, Chen R, Spielberger R, Cai J, Chen YY, Zumel S, Gaal K, Aoun P, Weisenburger DD, Kim YS. Coexpression of MYC and BCL2 protein in diffuse large B cell lymphoma predicts a poor outcome in patients treated with autologous hematopoietic stem cell transplantation (USCAP 2015).
  • Batra R, Weisenburger D, Snyder D, Bedell V, Murata-Collins J, Gaal K. Prognostic Significance of Chromosomal Aberrations in Philadelphia Chromosome Negative Metaphases during Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia (USCAP 2014).
  • Zhang N, Reddi DM, Weisenburger DD, Kim Y. Follicular Lymphoma with Marginal Zone Differentiation, an Institutional Experience (USCAP 2014).
  • Bautista-Quach MA, Nademanee A, Weisenburger DD, Chen W, Kim YS. Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules. Clin Breast Cancer. 2013;13(6):492-495. PMID 24267734
  • Kim YS, Wu H, Pawlowska AB, Bautista-Quach MA, Huang Q, Gaal K, Chang KL. Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C>T) KIT mutation, mimicking histiocytic neoplasm. Am J Surg Pathol. 2013;37(3):453-458. PMID 23388130
  • Pan ZG, Zhang QY, Lu ZB, Quinto T, Rozenvald IB, Liu LT, Wilson D, Reddy V, Huang Q, Wang HY, Ren YS. Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol. 2012;36(8):1129-1140. PMID 22790853
  • Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol 2008; 129(4):624-9.  PMID 18343790
     

Program Graduates
 
2019
Saba Ali, El Camino Pathology Group
Adam Cloe, Quest Diagnostic
Jayati Mallick
 
2018
David Cantu
Parwiz Siaghani, Long Beach Memorial Hospital
 
2017
Jerry Wong, Roswell Park Cancer Institute
Maryam Ameri, Community Hospital of San Bernardino
 
2016
Lawrence Low, Alta Bay East Pathology

2015
Liping Song, Midwest Pathology Associates
 
2014
Rashmi Batra, Santa Clara Valley Medical Center
Deepti Reddi, University of Washington
Nan Zhang, University of Buffalo
Kali Freeman, Yosemite Pathology Group
Tobi Quinto, UCLA Surgical Pathology Fellowship

2013
Marnelli Aguilar Bautista-Quach, Yosemite Pathology Group
 
2012
Hannah Wong, Diagnostic Pathology Medical Group
Zenggang Pan, University of Colorado, Denver
Aihong Liu, University of San Francisco
 
2011
Ji Lu, Kaiser Permanente, Northern California
Jyotsna Reddy, Kaiser Permanente, Sacramento
 
2010
Hung Luu, University of Texas, Southwestern
Mingyi Chen, University of California, Davis
Renuka Agrawal, Clarient
 
2009
Youn Kim, Kaiser Permanente, Bellflower
Monica Caro-Mosquera, Hoag Memorial Hospital
Angie Pham, Seattle, WA
 
2008
Steve Lum, The Queen's Medical Center
Kate Grimm, Clarient
 
2007
Veronica Rausei-Mills, Hoag Memorial Hospital
Sherif Rezk, University of California, Irvine